The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

Health and Human Services employees were told in March to remove 'nicknames' from email systems and signatures to comply with ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa ...

Hoagie rolls and sourdough and whole grain multigrain loaves from Upper Crust Bakery LP have all been recalled ...

AI is a transformational force in healthcare, but without cybersecurity as its foundation, it becomes a high-stakes gamble.

As food companies face pressure to eliminate artificial dyes, experts weigh in on the natural alternatives that could replace ...

IMAAVY TM (nipocalimab-aahu) is a first-in-class FcRn (neonatal Fc receptor) inhibitor, designed to reduce the levels of ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

The drug cytisinicline could help expand options for quitting smoking, and if approved by the FDA, would be the first new ...